Pain-motor integration refers to physiological processes responsible for mutual interaction between nociceptive and motor information in the central nervous system. Two separate lines of evidence support the hypothesis that pain-motor integration mechanisms operate in the human cerebral cortex. First, epidural motor cortex stimulation (MCS), as well as non-invasive brain stimulation (NIBS) protocols delivered over the primary motor cortex (M1), can both improve pain in patients with drug-resistant chronic pain. MCS and NIBS are thought to modulate M1 corticofugal descending inhibitory inputs to structures involved in the central processing of pain such as the thalamus and the periaqueductal grey (PAG) (Cruccu et al., 2016; Lefaucheur, 2016) . Second, experimental pain may affect the excitability as well as plasticity of specific circuits in the human motor system. Accordingly, over recent years, a growing number of authors have investigated experimentally the impact of chronic pain on long-term potentiation (LTP)-and depression (LTD)-like plasticity processes in M1, owing to pain-motor integration, in various neurological disorders (Suppa et al., 2013 (Suppa et al., , 2017 Naro et al., 2015) .
In this issue of Clinical Neurophysiology, Thapa et al. (2018) investigated possible changes in M1 LTP/LTD-like plasticity in individuals affected by chronic low back pain (cLBP). The study design consisted of two separate experimental sessions implying a single or double application of M1 anodal transcranial direct current stimulation (tDCS). As a measure of M1 plasticity, the authors measured and compared motor evoked potential (MEP) amplitudes, recorded at baseline and 0-30 min after tDCS ended. In healthy subjects, when delivering a single block of anodal tDCS (7 min of stimulation), as expected, MEPs increased in size at all the timepoints, suggesting M1 plasticity processes. By contrast, following the application of two blocks of anodal tDCS (first block of 7 min of tDCS followed by a second block of 5 min of tDCS, with an inter-block interval of 3 min), MEPs decreased in size in healthy controls, owing to homeostatic plasticity mechanisms, in line with a previous observation (Fricke et al., 2011) . Conversely, in individuals with cLBP, although a single block of anodal tDCS led to normal MEP facilitation, following the two-block tDCS protocol, MEPs remained abnormally facilitated. By demonstrating normal responses to a single block of anodal tDCS but abnormal responses to the two-block tDCS protocol, the authors provided the first evidence of normal plasticity but abnormal homeostatic plasticity in M1, in individuals with cLBP. Finally, there was no correlation between the patient's clinical features (e.g. pain duration and intensity scored by means of the numerical rating scale -NRS) and the abnormal MEP changes observed after the two-block tDCS protocol.
The study of Thapa et al. (2018) is characterized by several strengths. First, the study included a relatively large number of individuals manifesting with cLBP, a common chronic musculoskeletal pain disorder with a rather unclear pathophysiology. Second, the study design was based on the experimental investigation of cortical pain-motor integration processes in cLBP, by means of an advanced NIBS protocol (Fricke et al., 2011) . Third, by examining and comparing MEP changes induced by a single or double application of anodal tDCS, the authors compared mechanisms underlying plasticity and homeostatic plasticity in M1, both related to pain-motor integration, in individuals with cLBP.
Nonetheless, when interpreting the observations reported by Thapa et al. (2018) , several methodological points should be taken into account. The experimental investigation of possible changes in M1 LTP/LTD-like plasticity driven by chronic pain would have benefitted from the evaluation of the integrity of the peripheral and central nociceptive pathway in individuals with cLBP. To this purpose, laser-evoked potentials (LEPs) are currently available to examine the integrity of structures involved in the transmission and central processing of pain (Cruccu et al., 2010) . Peripheral or central nociceptive pathway alterations may induce M1 LTP/LTDlike plasticity changes, as demonstrated in different neurological conditions associated with pain of neuropathic as well as non-neuropathic origin (Chang et al., 2018) . Another comment concerns the sub-optimal description of chronic drug treatments in the individuals with cLBP enrolled in the present study. Several pharmacological agents, commonly used for symptomatic improvement of chronic pain syndromes, potentially affect M1 excitability and LTP/LTD-like plasticity processes (Nitsche et al., 2012; Ziemann et al., 2015) . For instance, gabapentinoids (gabapentin and pregabalin), antidepressant drugs (amitriptyline, duloxetine, etc.), opioid analgesics (oxycodone, tramadol, codeine, etc.) and finally, nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. acetaminophen/paracetamol), are all widely used in individuals with cLBP. Virtually all these pharmacological agents may affect measures of M1 excitability and LTP/LTD-like plasticity, as tested by NIBS protocols (Nitsche et al., 2012; Ziemann et al., 2015) . A further comment concerns the physiological interpretation of the findings reported by Thapa et al. (2018) . Homeostatic plasticity refers to high-order physiological processes able to prevent an
